A Study of HS-20094 in Chinese Adults With Overweight or Obesity

Summary

The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.

Timeline

Start

2024-11-16

Primary completion

2026-01-04

Completion

2026-01-30

Outcome

Met primary endpoint

release “In March 2026, the first Phase Ⅲ clinical study (HS-20094-301) of Olatorepatide in Chinese adults with obesity or overweight met its primary endpoint:” hspharm.com ↗

Drugs

Indications